174 related articles for article (PubMed ID: 37263876)
1. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
Ibrahim U; Bassil C; Chavez JC; Khimani F; Jain MD; Locke FL; Osman K; Lazaryan A
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):772-778. PubMed ID: 37263876
[No Abstract] [Full Text] [Related]
2. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
Portuguese AJ; Gauthier J; Tykodi SS; Hall ET; Hirayama AV; Yeung CCS; Blosser CD
Bone Marrow Transplant; 2023 Apr; 58(4):353-359. PubMed ID: 36575360
[TBL] [Abstract][Full Text] [Related]
3. Management of post-transplant lymphoproliferative disorders.
DeStefano CB; Desai SH; Shenoy AG; Catlett JP
Br J Haematol; 2018 Aug; 182(3):330-343. PubMed ID: 29741774
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults.
Rubinstein J; Toner K; Gross T; Wistinghausen B
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101446. PubMed ID: 36907642
[TBL] [Abstract][Full Text] [Related]
5. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
Green M
Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
[TBL] [Abstract][Full Text] [Related]
6. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
7. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
9. [Post-transplantation lymphoproliferative disorder in childhood].
Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorders.
Singavi AK; Harrington AM; Fenske TS
Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
[TBL] [Abstract][Full Text] [Related]
11. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.
Allen U; Preiksaitis J;
Am J Transplant; 2009 Dec; 9 Suppl 4():S87-96. PubMed ID: 20070701
[No Abstract] [Full Text] [Related]
12. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy.
Li PK; Tsang K; Szeto CC; Wong TY; To KF; Leung CB; Lui SF; Yu S; Lai FM
Am J Kidney Dis; 1998 Nov; 32(5):813-9. PubMed ID: 9820452
[TBL] [Abstract][Full Text] [Related]
13. [Post-transplant lymphoproliferative disorders].
Forsell S; Lang N
Rev Med Suisse; 2023 May; 19(827):964-968. PubMed ID: 37195110
[TBL] [Abstract][Full Text] [Related]
14. Post-Transplantation Lymphoproliferative Disorders in Adults.
Dierickx D; Habermann TM
N Engl J Med; 2018 Feb; 378(6):549-562. PubMed ID: 29414277
[No Abstract] [Full Text] [Related]
15. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
[TBL] [Abstract][Full Text] [Related]
16. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.
Hernani R; Sancho A; Amat P; Hernández-Boluda JC; Pérez A; Piñana JL; Carretero C; Goterris R; Gómez M; Saus A; Ferrer B; Teruel AI; Terol MJ; Solano C
Curr Res Transl Med; 2021 Oct; 69(4):103304. PubMed ID: 34303899
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
18. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
Dierickx D; Tousseyn T; De Wolf-Peeters C; Pirenne J; Verhoef G
Leuk Lymphoma; 2011 Jun; 52(6):950-61. PubMed ID: 21338285
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation.
Prockop SE; Vatsayan A
Cytotherapy; 2017 Nov; 19(11):1270-1283. PubMed ID: 28965834
[TBL] [Abstract][Full Text] [Related]
20. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
Tse E; Kwong YL
Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
